HAE Fail-to-Deliver
Haemonetics Corporation (HAE) operates in the Healthcare sector, specifically the Medical - Devices industry, with a market capitalization near $5.53B, listed on NYSE, employing roughly 3,009 people, carrying a beta of 0.54 to the broader market. Haemonetics Corporation is a healthcare enterprise dedicated to providing medical products and comprehensive solutions, structured into three main business areas: Plasma, Blood Center, and Hospital. Led by Christopher A. Simon, public since 1991-05-10.
No records carrying symbol HAE appear in the SEC's published NSCC CNS fails-to-deliver data for settlement dates August 22, 2026 through September 14, 2026.
Most recent fail-to-deliver in our records: August 21, 2026.
Frequently asked HAE fail-to-deliver questions
- Has HAE had any fails-to-deliver recently?
- No records carrying symbol HAE appear in the SEC's published NSCC CNS fails-to-deliver data for settlement dates August 22, 2026 through September 14, 2026. Most recent fail-to-deliver in our records: August 21, 2026. The SEC publishes the first half of each month at the month's end and the second half around the 15th of the next month, so this check covers settlement dates through September 14, 2026.
- What does it mean when HAE is absent from the SEC fails-to-deliver data?
- The SEC's files give the aggregate net balance of shares that failed to be delivered in NSCC's Continuous Net Settlement system, by security and settlement date. Since September 16, 2008 a security has a record for every settlement date on which that balance was above zero, and none when it was zero. This check is by symbol, so a fail reported only under a CUSIP or a former symbol is not counted.
Fail-to-deliver (FTD) data from the SEC tracks settlement failures where shares were not delivered within the standard settlement period. Persistent FTDs may indicate naked short selling or settlement issues and are monitored by regulators.
Learn how fails-to-deliver is reported and how to read the data →